Navigation Links
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Date:10/12/2009

tus, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.

Tardive Dyskinesia (TD): The risk of developing TD and the likelihood for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose increases. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations Fanapt should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia.

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including Fanapt. Patients with risk factors for diabetes mellitus who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Weight Gain: Based on the pooled data from the four placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the proportions of patients having a weight gain of greater than or equal to 7% body weight was 12% for Fanapt 10-16 mg/day, 18% for Fanapt 20-24 mg/day, and 13% for Fanapt (combined doses)
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
2. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
11. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Inc. (Nasdaq: CRDC ) today announced financial results ... Cardica,s management will hold a conference call at 4:30 ... provide an update on the company,s business. ... 2015, we reintroduced a modified MicroCutter XCHANGE® 30 suitable ... commercial release is focusing primarily on customers in Europe ...
(Date:5/6/2015)... May 6, 2015 Vanda Pharmaceuticals Inc. (Vanda) ... results for the first quarter ended March 31, 2015. ... record quarter for product sales driven by HETLIOZ and ... accessing the 80,000 Non-24 patients in the U.S., the ... patent exclusivity for Fanapt underscores the growth potential of ...
(Date:5/6/2015)... Systems, Inc. (NASDAQ: DCTH ), a specialty pharmaceutical ... emphasis on the treatment of primary and metastatic liver ... March 31, 2015.  Highlights of the ... quarterly product revenue of $0.44 million, an increase of ... 2014; , Activated a prospective patient registry in ...
Breaking Medicine Technology:Cardica Announces Fiscal 2015 Third Quarter Financial Results 2Cardica Announces Fiscal 2015 Third Quarter Financial Results 3Cardica Announces Fiscal 2015 Third Quarter Financial Results 4Cardica Announces Fiscal 2015 Third Quarter Financial Results 5Cardica Announces Fiscal 2015 Third Quarter Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 12Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8
... and AMSTERDAM, September 19, 2011 ... announced that a published report highlighting the development ... profile was published online in Breast Cancer ... is a part of Agendia,s Symphony™ suite of ...
... YORK, Sept. 19, 2011 Bayer HealthCare, one of ... $50,000 grant to support the Women,s International Leadership (WIL) ... external partnerships that Bayer HealthCare has established as part ... in 2008 to further develop an environment that fosters ...
Cached Medicine Technology:Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 2Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 3International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 2International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 3
(Date:5/6/2015)... May 06, 2015 As Hilo ... HIMSS EMR Adoption Model, the hospital looked for ... engagement and automate processes. The leadership team realized ... to electronic workflows, patient registration still required patients ... consents. With HIMSS Stage 7 attestation fast approaching, ...
(Date:5/6/2015)... Lewisberry, PA (PRWEB) May 06, 2015 A quality ... option for a functional yet practical way to raise chickens on ... coop by Chicken Coop Condo, it will have a chicken tractor ... It will last for many years, as it is able to ... help control which areas of the land are fertilized, and it ...
(Date:5/6/2015)... Experienced Vancouver air conditioning installation and ... they will now conduct their cooling services, including air ... to commercial and residential units. Strata complex air conditioning ... of technical knowledge as well as a professionally trained ... will take away any old air conditioning unit to ...
(Date:5/6/2015)... Chesapeake Regional Medical Center is the ... acquire Intuitive Surgical, Inc.’s latest model of the ... enhanced surgical technique capabilities, which can be used ... spectrum of specialties. Its advancements allow patients less ... times. , “As the only independent, community-based hospital ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3
... , MONDAY, Nov. 22 (HealthDay News) -- The pain of ... foot, elbow and lower back pain, a new study has ... osteoarthritis (OA) patients, aged 45 to 79, about pain in ... ankle or foot. Low back pain was significantly associated ...
... the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, ... Award 2010" in the biology category. He will receive ... the understanding of the structure and function of GTP-binding ... two other scientists, Professor Nicolai Cramer (Lausanne, Switzerland) and ...
... , MONDAY, Nov. 22 (HealthDay News) -- If teens, ... could be compromised, a new study suggests. Teens ... providers for fear of being judged, and are reluctant ... to researchers at Cincinnati Children,s Hospital Medical Center. ...
... STANFORD, Calif. Researchers at the Stanford University School ... three-dimensional cancers in a tissue culture dish for the ... divide and invade surrounding tissue will help physicians better ... new technique also provides a way to quickly and ...
... Amounts of Urinary Protein Predict More Rapid Cognitive Decline ... Warranted A new study has found that ... not traditionally considered clinically significant, strongly predict faster cognitive ... 1,200 women aged >70 years in the Nurses, Health ...
... Reporter , FRIDAY, Nov. 19 (HealthDay News) -- Computer imaging ... look after a "nose job," and the majority value the ... "morphing" software, used by plastic surgeons since the 1990s, appears ... said. "Having an image of an individual in front ...
Cached Medicine News:Health News:For Teens, Privacy May Trump Health Care 2Health News:Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes 2Health News:Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes 3Health News:Protein in the urine: A warning sign for cognitive decline 2Health News:Protein in the urine: A warning sign for cognitive decline 3Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 2Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 3
... Integre Duo is the first ... and green wavelengths. This advanced,laser ... instantly,select either a red or ... maximizes,treatment options and ensures effective,patient ...
... Gathering, managing, and transmitting data ... you were hired for. Dawnings ResultNet/Plus ... running your lab, not your communications ... with transmitting result data from largescale ...
... a comprehensive hemodynamic monitoring and information ... Patient demographics, clinical hemodynamic data, ... information all flow seamlessly into one ... data entry. Both images ...
Exxcel Soft ePTFE vascular graft, designed for exceptional kink resistance and crush resistance, maintains a Soft touch for easier handling during peripheral vascular bypass procedures and vascular a...
Medicine Products: